deltatrials
Terminated PHASE4 INTERVENTIONAL 1-arm NCT03212963

Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%

An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol Propionate Lotion, 0.05% in Subjects 12 to 16 Years 11 Months of Age With Plaque Psoriasis Receiving Two Weeks of Treatment

Sponsor: Sun Pharmaceutical Industries Limited

Conditions Plaque Psoriasis
Interventions Halobetasol Topical Lotion
Updated 12 times since 2017 Last updated: Dec 6, 2021 Started: Mar 21, 2017 Primary completion: Aug 12, 2019 Completion: Aug 12, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor's Decision

Other terminated trials from Sun Pharmaceutical Industries Limited

More terminations from Sun Pharmaceutical Industries Limited

Other Plaque Psoriasis trials with similar outcome

Browse all Plaque Psoriasis trials

Listed as NCT03212963, this PHASE4 trial focuses on Plaque Psoriasis and remains terminated or withdrawn. Sponsored by Sun Pharmaceutical Industries Limited, it has been updated 12 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshotRecruiting~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshotRecruiting~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshotRecruiting~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshotRecruiting~Dec 2018 – ~Nov 2019 · 11 months · monthly snapshotRecruiting~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshotCompleted~Dec 2019 – ~Oct 2020 · 10 months · monthly snapshotCompleted~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshotTerminated~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshotTerminated~Jan 2022 – ~Jul 2024 · 30 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 24 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE4

  3. Jan 2022 — Jul 2024 [monthly]

    Terminated PHASE4

  4. Jan 2021 — Jan 2022 [monthly]

    Terminated PHASE4

  5. Oct 2020 — Jan 2021 [monthly]

    Terminated PHASE4

    Status: Completed → Terminated

▶ Show 7 earlier versions

  1. Dec 2019 — Oct 2020 [monthly]

    Completed PHASE4

  2. Nov 2019 — Dec 2019 [monthly]

    Completed PHASE4

    Status: Recruiting → Completed

  3. Dec 2018 — Nov 2019 [monthly]

    Recruiting PHASE4

  4. Jun 2018 — Dec 2018 [monthly]

    Recruiting PHASE4

  5. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE4

  6. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE4

  7. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE4

    First recorded

Mar 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sun Pharmaceutical Industries Limited
Data source: Sun Pharmaceutical Industries Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations